Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

Published 4 months ago
Description
In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, a Pharmaceutical Executive commentary argues AI-driven patient support still can't replace human connection, and Jasper Therapeutics closes its acquisition of Kira Pharmaceuticals in a deal combining a three-asset immunology pipeline.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us